Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. TAM Receptor Inhibition-Implications for Cancer and the Immune System

    Research output: Contribution to journalReviewResearchpeer-review

  4. Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Adoptive cell therapy (ACT) for cancer represents a promising new treatment modality. ACT based on the administration of cytotoxic T cells genetically engineered to express a chimeric antigen receptor (CAR) recognizing CD19 expressed by B cell malignancies has been shown to induce complete lasting responses in patients with chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL). So far, eleven clinical trials including 99 CLL and ALL patients treated with CAR T cells targeting CD19 have been published, and the results from these trials are promising with impressive clinical responses in heavily pretreated patients. Thus, CAR T cell therapy has induced complete responses in both CLL and ALL, and surprisingly, current results indicate that patients with ALL are more prone to respond than are CLL patients. Importantly, the majority of CAR cell studies have observed severe therapy-associated toxicities, which needs attention. Herein we review current data and discuss key aspects of this powerful approach to treat and potentially cure B cell malignancies.

Original languageEnglish
JournalScandinavian Journal of Immunology
Volume82
Issue number4
Pages (from-to)307-19
Number of pages13
ISSN0300-9475
DOIs
Publication statusPublished - Oct 2015

    Research areas

  • Antigens, CD19, Humans, Immunotherapy, Adoptive, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, T-Lymphocytes, Cytotoxic

ID: 45944191